CN101209334B - Lung cancer-treating medicament and preparation thereof - Google Patents
Lung cancer-treating medicament and preparation thereof Download PDFInfo
- Publication number
- CN101209334B CN101209334B CN2007103017216A CN200710301721A CN101209334B CN 101209334 B CN101209334 B CN 101209334B CN 2007103017216 A CN2007103017216 A CN 2007103017216A CN 200710301721 A CN200710301721 A CN 200710301721A CN 101209334 B CN101209334 B CN 101209334B
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- rhizoma
- medicine
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a drug for the treatment of lung cancer and the preparation method thereof, the invention is a medicament which includes the raw materials with the following parts by weight for preparation: 7 to 9 parts of ginseng, 6 to 7 parts of zedoary, 5 to 7 parts of common burreed rhizome, 4 to 6 parts of Mongolian snakegourd root, 3 to 5 parts of honeycomb, 4 to 6 parts of Mongolian dandelion herb, 4 to 6 parts of heartleaf houttuynia herb, 2 to 3 parts of largehead atractylodes rhizome, 2 to 5 parts of Indian buead, 2 to 3 parts of largetrifoliolious bugbane rhizome, 2 to 3 parts of liquoric root, 1 to 2 parts of Chinese date, 2 to 5 parts of dried rehmannia root, 1 to 4 parts of white paeony root, 1 to 4 parts of Chinese angelica, 1 to 4 parts of cochinchinese asparagus root, 1 to 4 parts of dwarf lilyturf tuber, 6 to 9 parts of spreading hedyotis herb and 4 to 7 parts of Chinese magnoliavine fruit. The invention can be prepared into the dry powder by extraction and drying, and can also be prepared into various formulations according to the needs. The drug of the invention has certain effects for the treatment of lung cancer and various cancers, and the invention has the functions of strengthening body resistance, benefiting qi, nourishing lung, nourishing yin, suppressing yang, clearing heat, removing toxicity, promoting blood circulation, removing blood stasis, diminishing inflammation, easing pain and strengthening immune.
Description
Technical field
The present invention relates to treat lung cancer drugs and preparation method thereof.
Background technology
The traditional Chinese medical science is thought: lung being a delicate viscus, be the canopy of the heart, and main gas can be breathed, and occupies critical role in human body.Lung is subject to the pathogen puzzlement as body and extraneous alternative passage simultaneously, and various diseases take place.Pulmonary carcinoma is the abbreviation of primary bronchogenic carcinoma of lung, and it is meant the malignant tumor that occurs in bronchial mucosa and alveolar.The morbidity of pulmonary carcinoma has confidential relation with smoking and environmental air pollution.Along with The development in society and economy, the main hazard factor of pulmonary carcinoma does not obtain control corresponding, and the M ﹠ M of pulmonary carcinoma is progressively rising.
The type of pulmonary carcinoma and development: pulmonary carcinoma is the cancer that betides in the lung, also can be referred to as pulmonary carcinoma.After pulmonary carcinoma increases gradually, can transfer to lymph node, brain, bone etc. and locate.Histological type according to cancerous cell is divided, and pulmonary carcinoma comprises adenocarcinoma, scale cancer, small cell carcinoma, large cell carcinoma, adenosquamous carcinoma, adenoid cystic carcinoma, carcinoid, glutinous epidermal carcinoma, carcinosarcoma etc.Except that small cell carcinoma, other types are referred to as non-small cell carcinoma.
At present, the treatment of pulmonary carcinoma is based on doctor trained in Western medicine, and main method is to take operation, thoracic surgery, radiosurgery, chemotherapy, is generically and collectively referred to as western medical treatment.Clinical manifestation, list is used a kind of western medicine, unsatisfactory curative effect, and produce drug resistance.Import Western medicine particularly uses Western medicine not only to cost an arm and a leg, and in various degree toxic and side effects and untoward reaction are arranged, and shows as cough, phlegm dyspnea, myalgia, weak, nausea,vomiting,diarrhea, gastric ulcer, alopecia etc.At present, the domestic treatment policy that has adopted the combination of Chinese and Western medicine, but still do not have comparatively practical and specific Chinese medicine preparation.
Summary of the invention
Technical problem to be solved by this invention provides a kind of treatment lung cancer drugs and preparation method thereof, a kind of new medicine is provided, have practicality, have no side effect, can effectively treat central type carcinoma of lung, adenocarcinoma and small cell carcinoma in the pulmonary carcinoma, and the preparation method of this medicine is provided.
Technical problem to be solved by this invention is achieved through the following technical solutions:
A kind of treatment lung cancer drugs is the medicament by following weight portion raw material components preparation: Radix Ginseng 7-9, Rhizoma Curcumae 6-7, rhizoma sparganic 5-7, Radix Trichosanthis 4-6, Nidus Vespae 3-5, Herba Taraxaci 4-6, Herba Houttuyniae 4-6, Rhizoma Atractylodis Macrocephalae 2-3, Poria 2-5, Rhizoma Cimicifugae 2-3, Radix Glycyrrhizae 2-3, Fructus Jujubae 1-2, Radix Rehmanniae 2-5, Radix Paeoniae Alba 1-4, Radix Angelicae Sinensis 1-4, Radix Asparagi 1-4, Radix Ophiopogonis 1-4, Herba Hedyotidis Diffusae 6-9, Fructus Schisandrae Chinensis 4-7.
Described raw material is preferably following weight portion raw material components: Radix Ginseng 8.5, Rhizoma Curcumae 6.5, rhizoma sparganic 5.5, Radix Trichosanthis 4.5, Nidus Vespae 3.5, Herba Taraxaci 4.5, Herba Houttuyniae 4.5, the Rhizoma Atractylodis Macrocephalae 2.5, Poria 3, Rhizoma Cimicifugae 2.5, Radix Glycyrrhizae 2.5, Fructus Jujubae 1.5, the Radix Rehmanniae 3.5, the Radix Paeoniae Alba 2.5, Radix Angelicae Sinensis 2.5, Radix Asparagi 2.5, Radix Ophiopogonis 2.5, Herba Hedyotidis Diffusae 7.5, Fructus Schisandrae Chinensis 5.5.
The present invention also provides a kind of preparation method for the treatment of lung cancer drugs, may further comprise the steps:
A. take by weighing each raw medicinal material by weight;
B. with Rhizoma Curcumae, rhizoma sparganic, Radix Trichosanthis, Herba Taraxaci, Herba Houttuyniae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Cimicifugae, Radix Glycyrrhizae, Fructus Jujubae, the Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Asparagi, Radix Ophiopogonis, Herba Hedyotidis Diffusae and Fructus Schisandrae Chinensis, carry out the water distillation, extract its volatile oil;
C. the solid medicine material after the distillation adds the decocting secondary, and each amount of water was not advisable to have spice, merged decocting liquid twice, filter to get filtrate, after concentrating, add the ethanol of 90%-95%, make pure content reach 60%-80%, precipitate with ethanol, filter pure liquid, reclaim the ethanol reconcentration, concentrate the back and add Extraction oil, dry under the 40-46 degree, make dry extract 1;
D. Radix Ginseng, Poria and Nidus Vespae are added together the ethanol of 90%-95%, carry out reflux, extract,, extracting solution reclaims ethanol, and is dry under the environment of 40-46 degree, makes dry extract 2;
E. merge dry extract 1 and dry extract 2, be ground into powder, promptly.
F. after step e merges dry extract 1 and dry extract 2, can also further make required powder, unguentum, electuary and capsule according to a conventional method
Theory of Chinese medical science is thought: under the normal condition, human body is keeping the health status of YIN and YANG in a relative equilibrium, as because of " seven emotions " factors such as " six desire ", make imbalance between YIN and YANG, cause diseases such as " excess of YANG bringing about heat syndrome; excess of YIN bringing about cold syndrome ", " the healthy energy internal memory, heresy can not be done, the institute of heresy gathers; its gas must be empty ", it is basis that treatment is worked as with adjusting equilibrium between yin and yang, vigorate qi and replenish the blood.
Dialectical pulmonary carcinoma, " the case cause of disease " " pathogenesis " should be the negative and positive disequilibrium, excess of YIN leading to deficiency of YANG, vim and vigour can not normally be moved.Cold in blood then coagulates, and QI and blood is retarded by silt, three warmers Sheng heat, and taste are long-pending wet, insufficiency of lung-QI, immunologic hypofunction, thereby blood clotting then stagnates formation cancerous cell invasion and attack body.
The prescription of medicine of the present invention is: Radix Ginseng is monarch, and Rhizoma Curcumae, rhizoma sparganic are minister, and Radix Trichosanthis, Nidus Vespae, Herba Taraxaci, Herba Houttuyniae are assistant, and the Rhizoma Atractylodis Macrocephalae, Poria, Rhizoma Cimicifugae, Radix Glycyrrhizae, Fructus Jujubae are for making.
Radix Ginseng: Compendium of Material Medica is carried: " herbal classic " is top grade: release name: SHENCAO, Rhizoma Panacis Japonici, Herba Stellariae Saxatilis etc.Abnormal smells from the patient: sweet, be slightly cold, nontoxic.Cure mainly: mend five and hide, peace spirit, decide soul, spasmolytic throb with fear, except that pathogen, happy Fructus Alpiniae Oxyphyllae makes eye bright.Clothes are made light of one's life by commiting suicide and are prolonged life for a long time." herbal classic " treats the intestinal cold in the stomach, trusted subordinate's drum pain, and the costa sternales fullness due to adverse ascending of QI, cholera is told contrary, in the accent, only quenches one's thirst, promoting blood circulation, it is long-pending to mend heavily fortified point, makes us not forgetting." not Lu " main five kinds of strain and seven kinds of impairment, a little less than the deficient expectorant, preventing or arresting vomiting is told, and the tonifying five ZANG-organs six internal organs are kept god among the guarantor.The expectorant in the heart that disappears is controlled consumptive lung disease and insane disease, and cold air is contrary last, eats under the typhoid fever, and all void and the diverse and confused person of dreaminess are in addition.Rice steamer power is ended irritated, souring water." Li Xun " digesting and appetizing is controlled gas in the accent, kill the metal and stone poison of drug." bright greatly " controls lung stomach YANG QI deficiency, and insufficiency of lung-QI is short, the weak breath of losing heart, and during invigorating middle warmer is slow, pathogenic fire in the removing pathogen in the heart lung taste, the liquid of slaking thirst and help produce saliva." element " controls all deficient syndromes of male woman, the heating spontaneous perspiration, and dizzy fortune headache, food is told in regurgitation, and expectorant is cruel, slides to rush down chronic dysentery, and frequent micturition is dripping, overstrain internal injury, apoplexy heatstroke, flaccidity syndrome and arthralgia syndrome haematemesis hemoptysis, stranguria with blood metrorrhagia, tire all diseases in preceding puerperal." time treasure ", great scape was said: monarch drug: Radix Ginseng be medicine highly necessary, with the same merit of Radix Glycyrrhizae, the sweet temperature of Radix Ginseng, the gas in can tonifying the lung, lung qi is prosperous then four dirty all prosperous, smart spontaneous and shape is from containing, so all gas of lung master is also." Chinese pharmacopoeia is carried: go into spleen, lung, stomach three warps.Function cures mainly, and strongly invigorating primordial QI promotes the production of body fluid admittedly take off, and calms the nerves, and it is deficient to control impairment caused by overstrain ... all gas deficiency of body fluid
Rhizoma Curcumae: nature and flavor: toil, temperature, nontoxic, return through, go into liver, spleen, lung meridian.Function cures mainly: circulation of qi promoting, and removing blood stasis, removing food stagnancy, pain relieving is controlled trusted subordinate's distending pain, lump in the abdomen etc.
Rhizoma sparganic: nature and flavor: toil, flat, nontoxic, return through, go into liver, spleen, stomach warp.Function cures mainly: control lump in the abdomen, and coagulation of QI-blood, hard etc. in the skin ulcer.Ministerial drug: Rhizoma Curcumae and rhizoma sparganic compatibility, go into liver, spleen, lung, stomach, the kidney Five Classics.Blood in dispelling the stagnated QI, the broken disease of circulation of qi promoting, the two share, mutually beneficial shape.
Radix Trichosanthis: bitter, sweet, cold, promoting the production of body fluid to quench thirst.
Nidus Vespae: dispel the wind counteracting toxic substances, parasite killing.Treatment is swollen vicious.
Herba Taraxaci: heat-clearing and toxic substances removing, the diuresis eliminating stagnation is treated carbuncle toxin.
Herba Houttuyniae: control pneumonia, lung pus soup, lung abscess is spitted blood etc.
Liver,kidney,spleen, stomach warp are gone into by the last four flavor adjuvant drug compatibility sides of going into, beneficial vital essence, bone and muscle strengthening, separate vicious, heat clearing away and restlessness relieving, harmonizing yingfen and weifen is mended and is closed negative and positive.
The Rhizoma Atractylodis Macrocephalae, Poria, Rhizoma Cimicifugae, Radix Glycyrrhizae, Fructus Jujubae is compatible is messenger drug, the side's of going into effect, and the spleen reinforcing nourishing the stomach, suitable gas is supported lung, activating blood circulation to dissipate blood stasis, heat-clearing and toxic substances removing promotes immunity.
The Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, nourishing YIN and benefiting blood is enriched blood and is invigorated blood circulation, and separates meridian and relieving pain, tonifying five ZANG-organs.Radix Asparagi, Radix Ophiopogonis, nourshing Yin and drynsessmoistening prescription, lung heat clearing, pathogenic fire reducing.Herba Hedyotidis Diffusae, heat clearing away loose and become silted up, eliminating carbuncle detoxifcation, lung heat clearing fire, eliminating the pathogens from the lung heat, the function of foster lung stomach.The side's of going into contingent pulmonary carcinoma of treatment merges syndrome, and can alleviate toxic and side effects and untoward reaction that the Western medicine medication occurs.
In order to obtain further therapeutic effect, medicine of the present invention can also add Fructus Schisandrae Chinensis 3-6 part on the basis of above prescription.
Fructus Schisandrae Chinensis is gone into lung meridian, and the gas of astringing the lung is known as aurin in the medicine aspect Chinese medicine is controlled lung, and ancients are used as Fructus Schisandrae Chinensis the king in the medicine of controlling lung.
Medicine of the present invention adopts modernized Chinese medicine preparation technology to be prepared into multiple medicinal preparation for oral administration, especially powder, unguentum, electuary or capsule, decoction etc.
Compared with the prior art, beneficial effect of the present invention is embodied in:
1, medicine of the present invention has solid and sets upright, and QI invigorating is supported lung, nourishing YIN for suppressing the hyperactive YANG, and heat-clearing and toxic substances removing, activating blood circulation to dissipate blood stasis, anti-inflammatory analgesic, the function of enhance immunity has good curative effect to central type carcinoma of lung, adenocarcinoma and small cell carcinoma in the treatment pulmonary carcinoma.
2, compare with similar medicine, medicine of the present invention is with low cost, and is easy to use, has no side effect.
For proving above-mentioned advantage, medicine of the present invention has carried out the clinical clinical verification of following examples 1 powders, and curative effect is apparent in view.Curative effect is as follows:
1. test method
Adopt random packet, the positive drug parallel control, double blinding is observed, the multi-center clinical trial design
1.1 experimenter source and sample content
The experimenter derives from the outpatient service or the inpatient of each clinic test center.With reference to the regulation of " medicine registration management way " (trying) the relevant relevant sample content of III clinical trial phase, observation meets scheme case 600 examples.Treatment is organized in 500 examples, central type carcinoma of lung 220 examples, and adenocarcinoma, each 140 example of small cell carcinoma: in matched group 100 examples, central type carcinoma of lung 40 examples, adenocarcinoma, each 30 example of small cell carcinoma.
1.2. curative effect observation: disease is levied the scalar quantization table
Central type carcinoma of lung related symptoms and sign: fever caused by exogenous pathogens, the aversion to wind fear of cold, general pain, it is low voice speaking to have a stuffy nose, pharyngalgia, cough, floating pulse, thin white fur of tongue.
Adenocarcinoma related symptoms and sign: fever due to yin deficiency, cough, hemoptysis expectorant, weak, general pain, dysphoria, body of the tongue red drop, thick, yellow and greasy fur.
Small cell carcinoma related symptoms and sign: cough, breathe hard expectoration, lumbago shape.Arteries and veins is to trickle unable, thin white fur of tongue.
2. Therapeutic Method
(1) is subjected to reagent: the embodiment medicine.
(2) contrast medicine: blank.
3. the usage and dosage and the course of treatment:
Each 0.5 gram, 2 times on the one.
Test group, matched group were 1 course of treatment with 45 days all.
4. curative effect judging standard
5. the efficacy assessment standard of central type carcinoma of lung, adenocarcinoma, small cell carcinoma cardinal symptom or sign:
(1) clinic control: after finishing the course of treatment, Sx disappears.
(2) produce effects: after finishing the course of treatment, the symptom and sign classification reduces 2 grades.
(3) effective: after finishing the course of treatment, the symptom and sign classification reduces 1 grade.
(4) invalid: as not reach the standard of effectively stating.
6, statistical method
Measurement data adopts pairing or t check in groups, and enumeration data adopts the X2 check.
Clinical test results
6.1 subject age:
The analysis of clinical trial subject age (year)
| The example number | X±SD | T | P | |
| Treatment group matched group | 500 100 | 45.06±8.25 42.81±10.47 | 0.68 | 0.5001 |
6.2 experimenter's sex:
Clinical trial experimenter sex is analyzed (example)
| The example number | The male | The women | X 2 | P | |
| The treatment group | 500 | 212 | 288 | 0.52 | 0.470 |
| Matched group | 100 | 40 | 60 |
7. curative effect overall merit:
Central type carcinoma of lung curative effect comprehensive evaluation result (routine %)
| The example number | Cure (control) | Produce effects | Effectively | Invalid | Obvious effective rate | Effective percentage | |
| The treatment group | 220 | 70 | 92 | 42 | 16 | 41.80 | 92.72 |
Treatment group and matched group be (rank test): Z=2.34 relatively, P=0.0130.
Adenocarcinoma small cell carcinoma curative effect comprehensive evaluation result (example, %)
| The example number | Cure | Produce effects | Effectively | Invalid | Obvious effective rate | Effective percentage | |
| The treatment group | 140 | 28 | 88 | 38 | 14 | 62.80 | 90.00 |
Compare between group: P=0.021＜1
Small cell carcinoma curative effect comprehensive evaluation result (example, %)
| The example number | Control | Produce effects | Effectively | Invalid | Obvious effective rate | Effective percentage | |
| The treatment group | 140 | 25 | 45 | 38 | 14 | 54.38 | 88.52 |
Curative effect compares (rank test): Z=1.78, P=0.0742 between group.
8. safety adverse events: in process of the test, do not observe other obvious adverse reaction.
9. conclusion: medicine of the present invention has certain curative effect to treatment pulmonary carcinoma and multiple cancer, has to consolidate and sets upright, and QI invigorating is supported lung, nourishing YIN for suppressing the hyperactive YANG, heat-clearing and toxic substances removing, activating blood circulation to dissipate blood stasis, anti-inflammatory analgesic, the function of enhance immunity.
The case case is as follows:
Case 1: the man, 50 years old, the peasant through CT examination, was diagnosed as central type carcinoma of lung, and go to a doctor in May, 2004, and disease is seen: fever caused by exogenous pathogens, the aversion to wind fear of cold, general pain, it is low voice speaking to have a stuffy nose, pharyngalgia, cough, floating pulse, thin white fur of tongue.Through using medicine Fang Zhi of the present invention, after the agent of taking medicine, remission continues to take 29 doses, and transference cure recovers the labour force.Follow up a case by regular visits to not recurrence more than a year.
Case 2: the man, 48 years old, the peasant through CT examination, was diagnosed as adenocarcinoma, and go to a doctor in June, 2005, and disease is seen: fever due to yin deficiency, cough, hemoptysis expectorant, weak, general pain, dysphoria, body of the tongue red drop, thick, yellow and greasy fur.Control through executing, take 30 doses, remission with medicine of the present invention.Follow up a case by regular visits to not recurrence in 2 years.
Case 3: the woman, 49 years old, the peasant through CT examination, was diagnosed as small cell carcinoma, and go to a doctor in March, 2005, and symptoms including cough is breathed hard, expectoration, lumbago shape.Arteries and veins is to trickle unable, thin white fur of tongue.Control through executing, take medicine 10 doses, continue and obey 20 doses, transference cure with medicine of the present invention.Following up a case by regular visits to a year and a half does not recur.Case 4: the woman, 46 years old, the peasant through CT examination, was diagnosed as small cell carcinoma, and go to a doctor in June, 2004, symptoms including cough, phlegm dyspnea, symptoms such as heating.Control through executing, take 20 doses, transference cure with medicine of the present invention.Follow up a case by regular visits to not recurrence in 2 years.
The specific embodiment:
Embodiment 1
Powder
Raw material (kg): Radix Ginseng 8.5, Rhizoma Curcumae 6.5, rhizoma sparganic 5.5, Radix Trichosanthis 4.5, Nidus Vespae 3.5, Herba Taraxaci 3.6, Herba Houttuyniae 3.6, the Rhizoma Atractylodis Macrocephalae 2.5, Poria 3, Rhizoma Cimicifugae 2.5, Radix Glycyrrhizae .25, Fructus Jujubae 1.5, the Radix Rehmanniae 3.5, the Radix Paeoniae Alba 2.5, Radix Angelicae Sinensis 2.5, Radix Asparagi 2.5, Radix Ophiopogonis 2.5, Herba Hedyotidis Diffusae 7-9, Fructus Schisandrae Chinensis 3.6.
Preparation process is:
A. take by weighing various raw medicinal materials by weight;
B. with Rhizoma Curcumae, rhizoma sparganic, Radix Trichosanthis, Herba Taraxaci, Herba Houttuyniae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Cimicifugae, Radix Glycyrrhizae, Fructus Jujubae, the Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Asparagi, Radix Ophiopogonis, Herba Hedyotidis Diffusae and Fructus Schisandrae Chinensis, carry out the water distillation, extract its volatile oil;
C. the solid spice after the distillation adds the decocting secondary, and each amount of water was not advisable to have spice, merges twice decocting liquid and filters, get filtrate, after concentrating, add 90% ethanol, make ethanol content reach 60%, precipitate with ethanol filters, get filtrate, reclaim the ethanol reconcentration, concentrate the back and add Extraction oil, dry under 40 degree, make dry extract 1;
D. Radix Ginseng, Poria and Nidus Vespae are added together 90% ethanol, carry out reflux, extract,, extracting solution reclaims ethanol, and is dry under 40 degree environment, makes dry extract 2;
E. merge dry extract 1 and dry extract 2, be ground into powder and promptly get powder.
Embodiment 2
Unguentum
Raw material (kg): Radix Ginseng 7, Rhizoma Curcumae 6, rhizoma sparganic 5, Radix Trichosanthis 4, Nidus Vespae 3, Herba Taraxaci 4, Herba Houttuyniae 4, the Rhizoma Atractylodis Macrocephalae 2, Poria 2, Rhizoma Cimicifugae 2, Radix Glycyrrhizae 2, Fructus Jujubae 1, the Radix Rehmanniae 5, the Radix Paeoniae Alba 4, Radix Angelicae Sinensis 4, Radix Asparagi 4, Radix Ophiopogonis 4, Herba Hedyotidis Diffusae 9, the Radix Rehmanniae 5, the Radix Paeoniae Alba 4, Radix Angelicae Sinensis 4, Radix Asparagi 4, Radix Ophiopogonis 4, Herba Hedyotidis Diffusae 9, Fructus Schisandrae Chinensis 7.
Preparation process is:
A. take by weighing various raw medicinal materials by weight;
B. with Rhizoma Curcumae, rhizoma sparganic, Radix Trichosanthis, Herba Taraxaci, Herba Houttuyniae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Cimicifugae, Radix Glycyrrhizae, Fructus Jujubae, the Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Asparagi, Radix Ophiopogonis, Herba Hedyotidis Diffusae and Fructus Schisandrae Chinensis, carry out the water distillation, extract its volatile oil;
C. the solid spice after the distillation adds the decocting secondary, and each amount of water was not advisable to have spice, merges twice decocting liquid and filters, get filtrate, after concentrating, add 92% ethanol, make ethanol content reach 70%, precipitate with ethanol filters, get filtrate, reclaim the ethanol reconcentration, concentrate the back and add Extraction oil, dry under 43 degree, make dry extract 1;
D. Radix Ginseng, Poria and Nidus Vespae are added together 92% ethanol, carry out reflux, extract,, extracting solution reclaims ethanol, and is dry under 43 degree environment, makes dry extract 2;
E. merge dry extract 1 and dry extract 2, be ground into powder, further make unguentum.
Embodiment 3
Capsule
Raw material (kg): Radix Ginseng 9, Rhizoma Curcumae 7, rhizoma sparganic 7, Radix Trichosanthis 6, Nidus Vespae 5, Herba Taraxaci 6, Herba Houttuyniae 6, the Rhizoma Atractylodis Macrocephalae 3, Poria 5, Rhizoma Cimicifugae 3, Radix Glycyrrhizae 3, Fructus Jujubae 2.The Radix Rehmanniae 5, the Radix Paeoniae Alba 4, Radix Angelicae Sinensis 4, Radix Asparagi 4, Radix Ophiopogonis 4, Herba Hedyotidis Diffusae 9, Fructus Schisandrae Chinensis 7
Preparation process is:
A. take by weighing various raw medicinal materials by weight;
B carries out the water distillation with Rhizoma Curcumae, rhizoma sparganic, Radix Trichosanthis, Herba Taraxaci, Herba Houttuyniae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Cimicifugae, Radix Glycyrrhizae, Fructus Jujubae, the Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Asparagi, Radix Ophiopogonis, Herba Hedyotidis Diffusae and Fructus Schisandrae Chinensis, extracts its volatile oil;
C. the solid spice after the distillation adds the decocting secondary, and each amount of water was not advisable to have spice, merges twice decocting liquid and filters, get filtrate, after concentrating, add 96% ethanol, make ethanol content reach 80%, precipitate with ethanol filters, get filtrate, reclaim the ethanol reconcentration, concentrate the back and add Extraction oil, dry under 46 degree, make dry extract 1;
D. Radix Ginseng, Poria and Nidus Vespae are added together 96% ethanol, carry out reflux, extract,, extracting solution reclaims ethanol, and is dry under 46 degree environment, makes dry extract 2;
E. merge dry extract 1 and dry extract 2, be ground into powder, further make capsule.
Embodiment 4
Electuary
Raw material (kg): Radix Ginseng 8, Rhizoma Curcumae 6.5, rhizoma sparganic 6, Radix Trichosanthis 7, Nidus Vespae 4, Herba Taraxaci 5, Herba Houttuyniae 5, the Rhizoma Atractylodis Macrocephalae 2.5, Poria 3.5, Rhizoma Cimicifugae 2.5, Radix Glycyrrhizae 2.5, Fructus Jujubae 1.5.The Radix Rehmanniae 3.5, the Radix Paeoniae Alba 2.5, Radix Angelicae Sinensis 2.5, Radix Asparagi 2.5, Radix Ophiopogonis 2.5, Herba Hedyotidis Diffusae 7.5, Fructus Schisandrae Chinensis 5.
Preparation process:, but further make electuary with embodiment 1.
Claims (5)
1. the medicine of therapeutic community's type pulmonary carcinoma, adenocarcinoma and small cell carcinoma is the medicament by following weight portion raw material components preparation: Radix Ginseng 7-9, Rhizoma Curcumae 6-7, rhizoma sparganic 5-7, Radix Trichosanthis 4-6, Nidus Vespae 3-5, Herba Taraxaci 4-6, Herba Houttuyniae 4-6, Rhizoma Atractylodis Macrocephalae 2-3, Poria 2-5, Rhizoma Cimicifugae 2-3, Radix Glycyrrhizae 2-3, Fructus Jujubae 1-2, Radix Rehmanniae 2-5, Radix Paeoniae Alba 1-4, Radix Angelicae Sinensis 1-4, Radix Asparagi 1-4, Radix Ophiopogonis 1-4, Herba Hedyotidis Diffusae 6-9, Fructus Schisandrae Chinensis 4-7.
2. the medicine of therapeutic community according to claim 1 type pulmonary carcinoma, adenocarcinoma and small cell carcinoma, described raw material are following weight portion raw material components: Radix Ginseng 8.5, Rhizoma Curcumae 6.5, rhizoma sparganic 5.5, Radix Trichosanthis 4.5, Nidus Vespae 3.5, Herba Taraxaci 4.5, Herba Houttuyniae 4.5, the Rhizoma Atractylodis Macrocephalae 2.5, Poria 3, Rhizoma Cimicifugae 2.5, Radix Glycyrrhizae 2.5, Fructus Jujubae 1.5, the Radix Rehmanniae 3.5, the Radix Paeoniae Alba 2.5, Radix Angelicae Sinensis 2.5, Radix Asparagi 2.5, Radix Ophiopogonis 2.5, Herba Hedyotidis Diffusae 7.5, Fructus Schisandrae Chinensis 5.5.
3. the medicine of therapeutic community according to claim 1 type pulmonary carcinoma, adenocarcinoma and small cell carcinoma, described medicament is powder, unguentum, electuary or capsule.
4. the preparation method of a claim 1 or 2 described therapeutic community type pulmonary carcinoma, adenocarcinoma and small cell carcinoma medicine may further comprise the steps:
A. take by weighing each raw medicinal material by weight;
B. with Rhizoma Curcumae, rhizoma sparganic, Radix Trichosanthis, Herba Taraxaci, Herba Houttuyniae, the Rhizoma Atractylodis Macrocephalae, Rhizoma Cimicifugae, Radix Glycyrrhizae and Fructus Jujubae, the Radix Rehmanniae, the Radix Paeoniae Alba, Radix Angelicae Sinensis, Radix Asparagi, Radix Ophiopogonis, Herba Hedyotidis Diffusae and Fructus Schisandrae Chinensis carry out the water distillation, extract its volatile oil;
C. the solid spice after the distillation adds the decocting secondary, adds water at every turn and is not advisable to have spice, merges decocting liquid twice, filters to get filtrate, and concentrates the back and adds Extraction oil, and dry under the 40-46 degree, system gets dry extract 1;
D. Radix Ginseng, Poria and Nidus Vespae are added together the ethanol of 90%-95%, carry out reflux, extract,, extracting solution reclaims ethanol, and dry under 40-46 degree environment, system gets dry extract 2;
E. merge dry extract 1 and dry extract 2, be ground into powder, promptly.
5. according to the preparation method of the described therapeutic community of claim 4 type pulmonary carcinoma, adenocarcinoma and small cell carcinoma medicine, described step e is ground into powder, further makes required powder, unguentum, electuary and capsule then.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007103017216A CN101209334B (en) | 2007-12-25 | 2007-12-25 | Lung cancer-treating medicament and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007103017216A CN101209334B (en) | 2007-12-25 | 2007-12-25 | Lung cancer-treating medicament and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101209334A CN101209334A (en) | 2008-07-02 |
| CN101209334B true CN101209334B (en) | 2010-07-28 |
Family
ID=39609698
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007103017216A Expired - Fee Related CN101209334B (en) | 2007-12-25 | 2007-12-25 | Lung cancer-treating medicament and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101209334B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101869667B (en) * | 2009-04-21 | 2011-07-27 | 苏尔云 | Chinese herbal medicinal composition for treating lung cancer |
| CN105169270A (en) * | 2015-10-08 | 2015-12-23 | 郑晨昭 | Medicine for promoting NSCLC (non-small-cell lung cancer) postoperative recovery, preparation method and application method |
| CN106620439B (en) * | 2017-02-14 | 2019-11-12 | 九江市第一人民医院 | For the pharmaceutical composition of Postoperative analgesia, preparation and its application |
| CN109481609A (en) * | 2018-12-31 | 2019-03-19 | 肖丽丽 | It is a kind of for treating the Chinese medicine composition and preparation method of syndrome of intermin-gled phlegm and blood stasis lung cancer |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1228310A (en) * | 1998-03-09 | 1999-09-15 | 张富永 | Xiaoaisan powder for curing cancer |
| CN1249941A (en) * | 1999-07-22 | 2000-04-12 | 魏富林 | Oral Chinese medicine liquid for treating tumor |
| CN1483423A (en) * | 2002-09-19 | 2004-03-24 | 于天德 | Traditional Chinese medicine for treating cancer and preparation method thereof |
| CN1891290A (en) * | 2006-03-06 | 2007-01-10 | 喻可安 | Medicine for treating cancer |
-
2007
- 2007-12-25 CN CN2007103017216A patent/CN101209334B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1228310A (en) * | 1998-03-09 | 1999-09-15 | 张富永 | Xiaoaisan powder for curing cancer |
| CN1249941A (en) * | 1999-07-22 | 2000-04-12 | 魏富林 | Oral Chinese medicine liquid for treating tumor |
| CN1483423A (en) * | 2002-09-19 | 2004-03-24 | 于天德 | Traditional Chinese medicine for treating cancer and preparation method thereof |
| CN1891290A (en) * | 2006-03-06 | 2007-01-10 | 喻可安 | Medicine for treating cancer |
Non-Patent Citations (10)
| Title |
|---|
| 孙钢.肺癌的中医药治疗研究进展与思考.江苏中医21 1.2000,21(1),44-46. |
| 孙钢.肺癌的中医药治疗研究进展与思考.江苏中医21 1.2000,21(1),44-46. * |
| 张嘉丽.肺癌临床用药综述及展望.现代中西医结合杂志15 5.2006,15(5),681-684. |
| 张嘉丽.肺癌临床用药综述及展望.现代中西医结合杂志15 5.2006,15(5),681-684. * |
| 张霆.肺癌晚期治疗思路及体会.山东中医杂志26 3.2007,26(3),153-155. |
| 张霆.肺癌晚期治疗思路及体会.山东中医杂志26 3.2007,26(3),153-155. * |
| 范宏宇等.中医药治疗非小细胞肺癌的研究概况.中国中医基础医学杂志8 11.2002,8(11),67-69. |
| 范宏宇等.中医药治疗非小细胞肺癌的研究概况.中国中医基础医学杂志8 11.2002,8(11),67-69. * |
| 魏华等.晚期肺癌的中医药治疗.湖北中医杂志22 8.2000,22(8),20-21. |
| 魏华等.晚期肺癌的中医药治疗.湖北中医杂志22 8.2000,22(8),20-21. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101209334A (en) | 2008-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101209334B (en) | Lung cancer-treating medicament and preparation thereof | |
| TWI840312B (en) | A chinese medicinal composition and its application | |
| CN101518594B (en) | Anti-tumor immunity-enhancing traditional Chinese medicine preparation and preparation method thereof | |
| CN101468148B (en) | Chinese medicinal composition for treating coronary heart disease and cerebral arteriosclerosis, and method for preparing the same | |
| CN105250890A (en) | Traditional Chinese medicine for treating hyperlipidemia | |
| CN102600426A (en) | Chinese medicinal preparation for promoting blood circulation to remove blood stasis and preparation method thereof | |
| CN101745089B (en) | Medicament for treating stomach cancer and preparation method thereof | |
| CN115252691A (en) | Traditional Chinese medicine composition for treating qi stagnation and blood stasis type coronary heart disease angina | |
| CN107998305A (en) | A kind of Chinese medicine preparation for being used to treat coronary heart disease | |
| CN103860773A (en) | Traditional Chinese medicine composition for treating myocardial ischemia and preparation method thereof | |
| CN104707090A (en) | Chinese herbal formula for treating coronary heart disease | |
| CN102406865A (en) | Chinese medicinal composition for treating psoriasis | |
| CN103285328B (en) | Traditional Chinese medicine composition capsule for treating coronary heart diseases and preparation method thereof | |
| CN105194207A (en) | Traditional Chinese medicine composition and application thereof | |
| CN102205067B (en) | Traditional Chinese medicine composition for treating chronic urticaria | |
| CN105233078A (en) | Traditional Chinese medicine composition for treating viral hepatitis | |
| CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
| CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
| CN104491316B (en) | A kind of Chinese medicine preparation for the treatment of deficiency of QI in middle-JIAO type hyperplasia of prostate | |
| CN113827668B (en) | Traditional Chinese medicine compound preparation for treating degenerative gonarthritis and preparation method thereof | |
| CN106727752A (en) | Treat pharmaceutical composition of synovitis and preparation method thereof | |
| CN102614420A (en) | Chinese medicine preparation for curing atrophic glossitis | |
| CN105770520A (en) | Medicine preparation used for treating coronary heart disease and application thereof | |
| CN105582379A (en) | Traditional Chinese medicine composition for treating liver-stomach disharmony and preparation method of traditional Chinese medicine composition | |
| CN105770815A (en) | Folium artemisiae argyi-containing traditional Chinese medicine composition for treating postpartum collapse and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100728 Termination date: 20141225 |
|
| EXPY | Termination of patent right or utility model |